Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.5%. By the end of trading, Regeneron Pharmaceuticals rose $7.22 (2.4%) to $312.87 on heavy volume. Throughout the day, 1,043,622 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 692,900 shares. The stock ranged in a price between $301.97-$319.83 after having opened the day at $304.59 as compared to the previous trading day's close of $305.65. Other companies within the Drugs industry that increased today were:
), up 93.1%,
), up 23.7%,
), up 11.6% and
), up 9.6%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $28.5 billion and is part of the health care sector. Shares are up 72.5% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
- You can view the full Regeneron Pharmaceuticals Ratings Report.
On the negative front,
), down 96.4%,
), down 58.3%,
), down 40.1% and
Cellular Dynamics International
), down 14.3% , were all laggards within the drugs industry with
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.